461432-25-7: Dapagliflozin Tetraacetate
It is a biotransformation product of Dapagliflozin which is a sodium-glucose cotransporter 2 blocker dapagliflozin lowered the composite endpoint of cardiovascular death in a large population of patients having type 2 diabetes mellitus.
Additional information on CAS 461432-25-7
(2R, 3R, 4R, 5S, 6S)-2-(acetoxymethyl)-6-(4-chloro-3-(4-ethoxybenzyl)phenyl)tetrahydro-2H-pyran-3, 4, 5-triyl triacetate
Lemaire, Sébastien, and Didier Schils. “Development of Efficient Routes to Access C-Glycosides as SGLT-2 Inhibitors for the Treatment of Type 2 Diabetes.” Topics in Heterocyclic Chemistry, 2015, pp. 29–50, https://doi.org/10.1007/7081_2015_166.?Kato, Eri T., et al. “Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus.” Circulation, vol. 139, no. 22, May 2019, pp. 2528–36, https://doi.org/10.1161/circulationaha.119.040130.?
Other products related to dapagliflozin
|Name of Impurity||Catalogue No.|